Seminars in thrombosis and hemostasis最新文献

筛选
英文 中文
Comments to the International Council for Standardization in Hematology Guidance for New Lot Verification of Coagulation Reagents, Calibrators, and Controls.
IF 3.6 2区 医学
Seminars in thrombosis and hemostasis Pub Date : 2025-04-02 DOI: 10.1055/a-2572-1299
Marc Thelen, Marith van Schrojenstein Lantman, Anne Stavelin, Tze Ping Loh
{"title":"Comments to the International Council for Standardization in Hematology Guidance for New Lot Verification of Coagulation Reagents, Calibrators, and Controls.","authors":"Marc Thelen, Marith van Schrojenstein Lantman, Anne Stavelin, Tze Ping Loh","doi":"10.1055/a-2572-1299","DOIUrl":"https://doi.org/10.1055/a-2572-1299","url":null,"abstract":"<p><p>N.A.</p>","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143773308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacotherapy for Venous Thromboprophylaxis following Total Hip or Knee Arthroplasty: A Systematic Review and Network Meta-analysis. 全髋关节或膝关节置换术后静脉血栓预防的药物疗法:系统综述与网络 Meta 分析》。
IF 3.6 2区 医学
Seminars in thrombosis and hemostasis Pub Date : 2025-04-01 Epub Date: 2024-07-01 DOI: 10.1055/s-0044-1787996
Bryan Song Jun Yong, Ryan Ruiyang Ling, Ruiqi Li, Jane Wenjin Poh, Chuen Seng Tan, Sean Wei Loong Ho, Bram Rochwerg, Roopen Arya, Kollengode Ramanathan, Bingwen Eugene Fan
{"title":"Pharmacotherapy for Venous Thromboprophylaxis following Total Hip or Knee Arthroplasty: A Systematic Review and Network Meta-analysis.","authors":"Bryan Song Jun Yong, Ryan Ruiyang Ling, Ruiqi Li, Jane Wenjin Poh, Chuen Seng Tan, Sean Wei Loong Ho, Bram Rochwerg, Roopen Arya, Kollengode Ramanathan, Bingwen Eugene Fan","doi":"10.1055/s-0044-1787996","DOIUrl":"10.1055/s-0044-1787996","url":null,"abstract":"<p><p>The optimal pharmacological prophylaxis for venous thromboembolism (VTE) after hip or knee arthroplasty is uncertain. We conducted a systematic review and network meta-analysis to compare the efficacy and safety of various medications. We searched multiple databases for randomized clinical trials (RCTs) comparing medications (including factor Xa inhibitors, factor IIa inhibitor, warfarin, unfractionated heparin [UFH], low-molecular-weight heparin [LMWH], aspirin, pentasaccharide) for VTE prophylaxis post-arthroplasty. Outcomes included any postoperative VTE identified with screening, major bleeding, and death. We used LMWH as the main comparator for analysis and performed trial sequential analysis (TSA) for each pairwise comparison. Certainty of evidence was assessed using GRADE (Grading of Recommendations, Assessments, Developments and Evaluations). We analyzed 70 RCTs (55,841 participants). Factor Xa inhibitors decreased postoperative VTE significantly compared with LMWH (odds ratio [OR]: 0.55, 95% confidence interval [CI]: 0.44-0.68, high certainty). Pentasaccharides probably reduce VTE (OR: 0.61, 95% CI: 0.36-1.02, moderate certainty), while the factor IIa inhibitor dabigatran may reduce VTE (OR: 0.75, 95% CI: 0.40-1.42, low certainty). UFH probably increases VTE compared with LMWH (OR: 1.31, 95% CI: 0.91-1.89, moderate certainty), and other agents like warfarin, aspirin, placebo, and usual care without thromboprophylaxis increase VTE (high certainty). Factor Xa inhibitors may not significantly affect major bleeding compared with LMWH (OR: 1.06, 95% CI: 0.81-1.39, low certainty). No medications had a notable effect on mortality compared with LMWH (very low certainty). TSA suggests sufficient evidence for the benefit of factor Xa inhibitors over LMWH for VTE prevention. Compared with LMWH and aspirin, factor Xa inhibitors are associated with reduced VTE after hip or knee arthroplasty, without an increase in bleeding and likely no impact on mortality.</p>","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"290-300"},"PeriodicalIF":3.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141477365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intravenous Direct Thrombin Inhibitors for Acute Venous Thromboembolism or Heparin-Induced Thrombocytopenia with Thrombosis in Children: A Systematic Review of the Literature. 静脉注射直接凝血酶抑制剂治疗儿童急性静脉血栓栓塞症或肝素诱发的血小板减少伴血栓形成:文献的系统回顾。
IF 3.6 2区 医学
Seminars in thrombosis and hemostasis Pub Date : 2025-04-01 Epub Date: 2024-10-07 DOI: 10.1055/s-0044-1791534
Amy L Kiskaddon, Josh Branstetter, Pam Williams, Vera Ignjatovic, Amanda Memken, Kristopher Wilhoit, Neil A Goldenberg
{"title":"Intravenous Direct Thrombin Inhibitors for Acute Venous Thromboembolism or Heparin-Induced Thrombocytopenia with Thrombosis in Children: A Systematic Review of the Literature.","authors":"Amy L Kiskaddon, Josh Branstetter, Pam Williams, Vera Ignjatovic, Amanda Memken, Kristopher Wilhoit, Neil A Goldenberg","doi":"10.1055/s-0044-1791534","DOIUrl":"10.1055/s-0044-1791534","url":null,"abstract":"<p><p>Intravenous direct thrombin inhibitors (DTIs) are used for thromboembolic disorders. This systematic review aims to characterize intravenous DTI agents, dosing, monitoring strategies (or use), bleeding, and mortality, in pediatric patients with acute venous thromboembolism (VTE) or heparin-induced thrombocytopenia with thrombosis (HITT). MEDLINE, Embase, and Cochrane's CENTRAL were searched from inception through July 2023. Case series, retrospective studies, and prospective studies providing per-patient or summary data for patients < 18 years of age with VTE or HITT treated with an intravenous DTI were included. Selection and data extraction were conducted independently by two reviewers. Sixteen studies (7 case reports, 1 case series, 5 retrospective studies, 3 prospective studies) with 85 patients were included. Target conditions included acute VTE in 54 (64%) and HITT in 31 (36%) patients. Bivalirudin, argatroban, and lepirudin were used in 52 (61%), 27 (32%), and 6 (7%) patients, respectively. Fifty-two (61%) patients received a bolus dose, and weighted mean infusion rates for bivalirudin, argatroban, and lepirudin were 0.2 mg/kg/hr, 1.2 mcg/kg/min, and 0.15 mg/kg/hr, respectively. The activated partial thromboplastin time was utilized for monitoring in 82 (96%) patients. Complete or partial thrombus resolution was reported in 53 (62%) patients, mortality in 6 (7%) patients, and bleeding complications in 14 (16%) patients. In this systematic review involving 85 pediatric patients treated with an intravenous DTI for acute VTE or HITT, bivalirudin was the most commonly utilized agent, with a rate of resolution over 60% despite a high acuity in the population studied. Prospective collaborative studies are warranted to establish optimal dosing and further characterize VTE and bleeding outcomes.</p>","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"329-334"},"PeriodicalIF":3.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142393065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mendelian Randomization Provides No Evidence for the Bidirectional Relationship between Type 2 Diabetes and Venous Thromboembolism in East Asians and African Americans. 孟德尔随机法无法证明东亚人和非裔美国人中 2 型糖尿病与静脉血栓栓塞之间的双向关系。
IF 3.6 2区 医学
Seminars in thrombosis and hemostasis Pub Date : 2025-04-01 Epub Date: 2024-07-19 DOI: 10.1055/s-0044-1788568
Jiawen Lu, Zhenqian Wang
{"title":"Mendelian Randomization Provides No Evidence for the Bidirectional Relationship between Type 2 Diabetes and Venous Thromboembolism in East Asians and African Americans.","authors":"Jiawen Lu, Zhenqian Wang","doi":"10.1055/s-0044-1788568","DOIUrl":"10.1055/s-0044-1788568","url":null,"abstract":"","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"348-350"},"PeriodicalIF":3.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141727736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of hematocrit on coagulation measured by rotational thromboelastometry in healthy subjects and patients with polycythemia.
IF 3.6 2区 医学
Seminars in thrombosis and hemostasis Pub Date : 2025-04-01 DOI: 10.1055/a-2570-4455
Marie Martin, Elie Nader, Hamdi Rezigue, Yesim Dargaud, Celine Renoux, Philippe Joly, Mael Heiblig, Christophe Nougier, Philippe Connes
{"title":"Impact of hematocrit on coagulation measured by rotational thromboelastometry in healthy subjects and patients with polycythemia.","authors":"Marie Martin, Elie Nader, Hamdi Rezigue, Yesim Dargaud, Celine Renoux, Philippe Joly, Mael Heiblig, Christophe Nougier, Philippe Connes","doi":"10.1055/a-2570-4455","DOIUrl":"https://doi.org/10.1055/a-2570-4455","url":null,"abstract":"<p><p>Thrombotic and cardiovascular events are among the leading causes of death for patients with polycythemia, more specifically for those with primary origin. It has been suggested that the high hematocrit would favor hypercoagulability. However, the impact of hematocrit on coagulation in patients with polycythemia has not been investigated so far. The aim of our study was to compare the coagulation profiles of healthy subjects and patients with polycythemia, and to evaluate the in-vitro impact of hematocrit on coagulation. Blood from healthy individuals (N=100 for blood viscosity; N=19 for coagulation) and patients with primary/secondary polycythemia (N=29 for blood viscosity; N=20 for coagulation) was used to perform measurements at native hematocrit. The impact of hematocrit modulation (20% vs 50%) on coagulation was tested in-vitro in 9 healthy subjects and 19 patients with polycythemia. Blood viscosity was measured by viscosimetry and coagulation and fibrinolysis by rotational thromboelastometry. In patients with polycythemia, hematocrit and blood viscosity were higher, clotting time was prolonged and clot lysis was faster compared to healthy individuals. Our in-vitro results showed that the clotting time was faster and the clot firmness higher at 20% vs 50% hematocrit for both populations, without any difference between the two populations at a given hematocrit. Our findings suggest that the interpretation of thromboelastometry results should be approached with caution in patients with high hematocrit. The in-vivo hypercoagulable state of patients with polycythemia is probably the consequence of changes in hemodynamic conditions attributed to blood hyper-viscosity, that may promote venous stasis and platelet margination.</p>","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive Mendelian Randomization Analysis of Smoking and Its Effects on Venous Thromboembolism. 吸烟及其对静脉血栓栓塞的影响的综合孟德尔随机分析。
IF 3.6 2区 医学
Seminars in thrombosis and hemostasis Pub Date : 2025-04-01 Epub Date: 2024-12-17 DOI: 10.1055/s-0044-1800980
Yuhong Li, Ling Tong, Youqian Zhang, Birun Huang, Liping Zhu
{"title":"Comprehensive Mendelian Randomization Analysis of Smoking and Its Effects on Venous Thromboembolism.","authors":"Yuhong Li, Ling Tong, Youqian Zhang, Birun Huang, Liping Zhu","doi":"10.1055/s-0044-1800980","DOIUrl":"10.1055/s-0044-1800980","url":null,"abstract":"<p><p>An increasing number of Mendelian randomization (MR) studies have evaluated the causal link between smoking and venous thromboembolism (VTE). However, previous studies often rely on single genetic variants related to smoking quantity and exhibit various other shortcomings, making them prone to pleiotropy and potentially leading to imprecise causal estimates. Thus, the deeper causal mechanisms remain largely unexplored. This MR study reassessed the causal relationship between smoking and VTE, including its subtypes-deep vein thrombosis (DVT) and pulmonary embolism (PE). Data on VTE were sourced from the FinnGen consortium with nonoverlapping sample sizes. The smoking phenotypes analyzed included smoking initiation, lifetime smoking, the number of cigarettes smoked per day by both current and former smokers (CigDay), and total pack-years of smoking in adulthood. The primary analytical method was inverse-variance-weighted (IVW), supplemented by multiple verification methods to ensure robust results. Statistical rigor was ensured through LDtrait pruning and Steiger filtering for reverse causation, with comprehensive sensitivity analyses including RadialMR confirming the findings' robustness. After Bonferroni correction, this study demonstrates significant causal evidence linking lifetime smoking with the incidence of VTE (odds ratio [OR]<sub>IVW</sub> = 1.50, 95% confidence interval [CI] 1.21-1.85, <i>p</i> = 1.75 × 10<sup>-4</sup>) and PE (OR<sub>IVW</sub> = 1.69, 95% CI 1.25-2.28, <i>p</i> = 6.55 × 10<sup>-4</sup>), and suggestive evidence with DVT, consistent in direction with previous studies but showing considerable differences in effect sizes and significance. Additionally, CigDay (past and current) increases the risks of VTE and DVT, while no causal link was found between smoking initiation and VTE or its subtypes (<i>p</i> < 0.05), both directly contradicting previous conclusions. Furthermore, our study is the first to suggest a causal link between pack-years and an increased risk of VTE. This MR study employed rigorous statistical pruning of its instrumental variables, using the most comprehensive smoking phenotype to date. It successfully mitigated biases such as winner's curse, yielding causal effect results distinct from previous studies.</p>","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"279-289"},"PeriodicalIF":3.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hereditary Thrombophilia: A Case of Subacute Pulmonary Embolism in a 68-Year-Old Female with a Mutation in the PROC Gene. 遗传性血栓性疾病:一例 PROC 基因突变的 68 岁女性亚急性肺栓塞病例。
IF 3.6 2区 医学
Seminars in thrombosis and hemostasis Pub Date : 2025-04-01 Epub Date: 2024-08-16 DOI: 10.1055/s-0044-1788304
Ziyang Chen, Hualan Wu, Yuan Xu, Tao Gu, Deping Liu, Ming Lan
{"title":"Hereditary Thrombophilia: A Case of Subacute Pulmonary Embolism in a 68-Year-Old Female with a Mutation in the PROC Gene.","authors":"Ziyang Chen, Hualan Wu, Yuan Xu, Tao Gu, Deping Liu, Ming Lan","doi":"10.1055/s-0044-1788304","DOIUrl":"10.1055/s-0044-1788304","url":null,"abstract":"","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"351-354"},"PeriodicalIF":3.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141996400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recurrent Thromboembolism in Pediatric Congenital Heart Disease: Cumulative Incidence and Prognostic Factors. 儿童先天性心脏病复发性血栓栓塞:累积发病率和预后因素。
IF 3.6 2区 医学
Seminars in thrombosis and hemostasis Pub Date : 2025-04-01 Epub Date: 2024-12-18 DOI: 10.1055/s-0044-1800967
Amy L Kiskaddon, Therese M Giglia, Marisol Betensky, Nhue L Do, Daniel M Witt, Arabela C Stock, Ernest K Amankwah, Jamie L Fierstein, Dina Ashour, Vera Ignjatovic, James A Quintessenza, Neil A Goldenberg
{"title":"Recurrent Thromboembolism in Pediatric Congenital Heart Disease: Cumulative Incidence and Prognostic Factors.","authors":"Amy L Kiskaddon, Therese M Giglia, Marisol Betensky, Nhue L Do, Daniel M Witt, Arabela C Stock, Ernest K Amankwah, Jamie L Fierstein, Dina Ashour, Vera Ignjatovic, James A Quintessenza, Neil A Goldenberg","doi":"10.1055/s-0044-1800967","DOIUrl":"10.1055/s-0044-1800967","url":null,"abstract":"<p><p>Congenital heart disease (CHD) is a risk factor for thromboembolism (TE). Data describing the rate of, and risk factors associated with, recurrent TE in children with CHD are limited. We prospectively evaluated TE recurrence risk in children with CHD and acute TE and investigated clinical risk factors associated with recurrent TE. Patients < 21 years of age with CHD and acute TE were enrolled in a single-institutional prospective inception cohort study (July 2013-April 2024). Descriptive statistics summarized variables including CHD and thrombus characteristics, antithrombotic regimens, bleeding, and recurrent TE. Multivariable logistic regression determined risk factors for recurrent TE. Among 40 children with CHD and acute TE, 13 (33%) developed ≥ 1 recurrent TE (arterial <i>n</i> = 1 [6%], venous <i>n</i> = 15 [83%], venous + arterial <i>n</i> = 2 [11%]) at a median time of 86 (interquartile range, 45-112) days postdiagnosis of the index TE. One-year cumulative incidence of recurrent TE was 38%. Twelve (67%) recurrent TE events were central venous catheter (CVC)-related. In univariable analyses, immobility (46% vs. 7%, <i>p</i> = 0.01), the presence of a CVC (69% vs. 30%, <i>p</i> = 0.02), and lower extremity index venous TE (89% vs. 41%, <i>p</i> = 0.04) were associated with TE recurrence. After adjustment for other potential risk factors via multivariable logistic regression, immobility (adjusted odds ratio [OR] 13.2, 95% confidence interval [CI] 1.16-151.3, <i>p</i> = 0.04) and the presence of a CVC (adjusted OR 5.28, 95% CI 1.03-27.1, <i>p</i> = 0.05) remained as independent risk factors for recurrent TE. The 1-year risk of TE recurrence was high among pediatric patients with CHD and acute TE. Immobility and the presence of CVC were independent risk factors for recurrent TE. Multicenter prospective cohort studies are warranted to substantiate and expand upon these important findings.</p>","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"335-342"},"PeriodicalIF":3.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142855532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vascular Pathogenesis in Acute and Long COVID: Current Insights and Therapeutic Outlook. 急性和长期 COVID 的血管发病机制:当前见解和治疗展望。
IF 3.6 2区 医学
Seminars in thrombosis and hemostasis Pub Date : 2025-04-01 Epub Date: 2024-09-30 DOI: 10.1055/s-0044-1790603
Arneaux Kruger, David Joffe, Graham Lloyd-Jones, Muhammed Asad Khan, Špela Šalamon, Gert J Laubscher, David Putrino, Douglas B Kell, Etheresia Pretorius
{"title":"Vascular Pathogenesis in Acute and Long COVID: Current Insights and Therapeutic Outlook.","authors":"Arneaux Kruger, David Joffe, Graham Lloyd-Jones, Muhammed Asad Khan, Špela Šalamon, Gert J Laubscher, David Putrino, Douglas B Kell, Etheresia Pretorius","doi":"10.1055/s-0044-1790603","DOIUrl":"10.1055/s-0044-1790603","url":null,"abstract":"<p><p>Long coronavirus disease 2019 (COVID-19)-a postacute consequence of severe acute respiratory syndrome coronavirus 2 infection-manifests with a broad spectrum of relapsing and remitting or persistent symptoms as well as varied levels of organ damage, which may be asymptomatic or present as acute events such as heart attacks or strokes and recurrent infections, hinting at complex underlying pathogenic mechanisms. Central to these symptoms is vascular dysfunction rooted in thrombotic endothelialitis. We review the scientific evidence that widespread endothelial dysfunction (ED) leads to chronic symptomatology. We briefly examine the molecular pathways contributing to endothelial pathology and provide a detailed analysis of how these cellular processes underpin the clinical picture. Noninvasive diagnostic techniques, such as flow-mediated dilation and peripheral arterial tonometry, are evaluated for their utility in identifying ED. We then explore mechanistic, cellular-targeted therapeutic interventions for their potential in treating ED. Overall, we emphasize the critical role of cellular health in managing Long COVID and highlight the need for early intervention to prevent long-term vascular and cellular dysfunction.</p>","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"256-271"},"PeriodicalIF":3.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142353072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Secondary Anticoagulation Use in Patients < 21 Years Old following Primary Anticoagulant Treatment for Provoked Venous Thromboembolism: Findings from the Kids-DOTT Trial. 小于 21 岁的患者因诱发静脉血栓栓塞而接受初级抗凝治疗后的二次抗凝治疗:Kids-DOTT 试验结果。
IF 3.6 2区 医学
Seminars in thrombosis and hemostasis Pub Date : 2025-04-01 Epub Date: 2024-09-19 DOI: 10.1055/s-0044-1790572
Hope P Wilson, Maua Mosha, Alexandra Miller, Marisol Betensky, Ernest Amankwah, John Fargo, Courtney D Thornburg, Cristina Tarango, Suchitra Acharya, Christoph Male, Shalu Narang, Sam Schulman, Neil A Goldenberg
{"title":"Secondary Anticoagulation Use in Patients < 21 Years Old following Primary Anticoagulant Treatment for Provoked Venous Thromboembolism: Findings from the Kids-DOTT Trial.","authors":"Hope P Wilson, Maua Mosha, Alexandra Miller, Marisol Betensky, Ernest Amankwah, John Fargo, Courtney D Thornburg, Cristina Tarango, Suchitra Acharya, Christoph Male, Shalu Narang, Sam Schulman, Neil A Goldenberg","doi":"10.1055/s-0044-1790572","DOIUrl":"10.1055/s-0044-1790572","url":null,"abstract":"","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"343-347"},"PeriodicalIF":3.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11908955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142294438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信